Compare Altria Group Inc (MO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Recursion Pharmaceuticals Inc — how do they compare? Altria Group Inc trades at $67.92 (market cap $113.83B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Altria Group Inc is far larger — about 61.2× Recursion Pharmaceuticals Inc's market cap, and Altria Group Inc pays a 6.51% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MO | RXRX | |
|---|---|---|
Market Cap | $113.83B | $1.86B |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $6.79 |
52-Week Low | $54.72 | $2.84 |
Enterprise Value | $136.04B | $1.38B |
Dividend Yield | 6.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $68.18, down 1.02% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock offers a high dividend yield of 6.45% following its 61st annual increase. Recent earnings show mixed quarterly results, with Q1 2026 beating expectations but Q2 2026 missing. Revenue remains stable around $20.1 billion (2025), with strong profitability margins, though net income declined to $6.95 billion in 2025 from $11.3 billion in 2024. Analyst consensus is bullish with a $68.50 price target.
MO presents a value opportunity with a low P/E of 14.35 and robust cash flows supporting dividends, but faces risks from regulatory lawsuits, declining cigarette volumes, and high debt levels. The stock's appeal hinges on dividend sustainability amid secular challenges in the tobacco industry.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
